Shots:

• The US FDA has approved Elucirem for contrast-enhanced MRI
• The approval was based on the 2 P-III studies of gadopiclenol (0.05mmol/kg) vs gadobutrol (0.1mmol/kg) which demonstrated that gadopiclenol leads to non-inferior results in brain and body MRI, contrast enhancement & diagnostic efficacy at half of the gadolinium dosing of other GBCAs, no safety signals were reported & the adverse reactions were similar for both products
• Elucirem is a new macrocyclic gadolinium-based contrast agent with high relaxivity indicated for adults & children aged ≥2yrs. & can be utilized with MRI to detect lesions with abnormal vascularity in CNS & other areas. The product will be marketed by Guerbet in the US in a bottle and pre-filled syringe form

Ref: Guerbet | Image:  Guerbet